SecBot SecBot
8-K ·Filed Nov 4, 2026

STE

STERIS plc
BULLISH
Impact 6/10
Horizonweeks Processed12d 5h ago SEC0001628280-26-070220
Killer combo: Earnings + restructuring announcement
Actionable Insight ▲ Bullish

The raised EPS guidance and strong Life Sciences performance are positive, but the second restructuring plan in two quarters signals ongoing margin pressure in Healthcare. Watch the Q3 earnings call for details on Xodus Medical acquisition integration and whether the restructuring savings materialize as planned.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

STERIS reported fiscal Q2 2027 results with revenue of $1.59B (+9% YoY) and adjusted EPS of $2.94, both above consensus estimates of $1.56B and $2.68. The company raised its full-year adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, citing solid underlying performance and tariff refunds. However, the company also announced a new $45M restructuring plan (on top of a prior plan) with $25M in charges already recorded in Q2, primarily in the Healthcare segment, signaling ongoing cost pressures.

Key Financial Metrics

EPS (Adj.)
$2.94
est $2.68 · +9.7% · GAAP: $2.19
Revenue
$1.6B
est $1.6B · +1.8% · +8.8% YoY
Rating
beat
Guidance
7-8% as reported growth
raised
Free Cash Flow
$492.5M
Gross Margin
44.7%

Key Facts

  • Q2 revenue $1.59B, +9% YoY, above $1.56B consensus
  • Q2 adjusted EPS $2.94, above $2.68 consensus (surprise +9.7%)
  • Q2 GAAP EPS $2.19 vs $1.94 YoY
  • Full-year adjusted EPS guidance raised to $11.35-$11.55 from $11.10-$11.30
  • Revenue growth guidance unchanged at 7-8% as reported, 6-7% organic constant currency
  • Life Sciences segment revenue +18% YoY; segment outlook raised to 9-10% growth
  • New $45M restructuring plan approved in Q2, with $25M in charges recorded
  • Restructuring includes facility realignment, product rationalization, primarily in Healthcare
  • Annualized savings of ~$9M expected from restructuring, full benefit in fiscal 2029+
  • First-half free cash flow $492.5M vs $527.7M prior year, down due to working capital
  • Tariff refunds provided ~$0.18 benefit to revised EPS guidance
  • Company repurchased $215.9M in shares YTD vs $111.1M prior year

Financial Impact

Q2 revenue $1.59B vs $1.56B consensus; adjusted EPS $2.94 vs $2.68 consensus; FY guidance raised by $0.25 at midpoint

revenueepsguidancerestructuring charges

Segment Breakdown

SegmentRevenueGrowth
Healthcare$1.1B+8.6%
Applied Sterilization Technologies$295.6M+5.0%
Life Sciences$170.6M+17.7%

Risk Factors

  • Restructuring charges of $45M indicate underlying cost pressures, particularly in Healthcare
  • Free cash flow declined 6.7% in H1 due to working capital drag
  • AST segment growth outlook lowered to 6-7% from 7-8%
  • Tariff refunds boosting EPS are non-recurring; underlying tariff costs remain at $15M/quarter
  • Backlog disclosure to be discontinued in fiscal 2028, reducing visibility

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070220
Document: ste-20261104.htm0001628280-26-070220
Document: 0001628280-26-070220-index-headers.html0001628280-26-070220
Document: 0001628280-26-070220-index.html0001628280-26-070220
Document: 0001628280-26-070220.txt0001628280-26-070220
8-K Data (Synthetic)0001628280-26-070220

Track record

21 reports on STE

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 23
  2. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $261.91 +3.34% settles Nov 19
  5. Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $261.91 +2.20% settles Nov 18
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
  7. Nov 4, 202612d ago 8-K Bullish 6/10 Viewing No price data
  8. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
  9. Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $261.91 +12.82% ▲ +9.47% +14.19% vs SPY
  10. Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $261.91 +18.25% ▲ +3.17% +3.61% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026